STOCK TITAN

Emergent Biosolutions Inc - EBS STOCK NEWS

Welcome to our dedicated page for Emergent Biosolutions news (Ticker: EBS), a resource for investors and traders seeking the latest updates and insights on Emergent Biosolutions stock.

Emergent BioSolutions Inc (NYSE: EBS) is a leader in developing medical countermeasures for public health threats, with a focus on biodefense and emergency response solutions. This page provides investors and stakeholders with centralized access to official press releases, regulatory updates, and strategic developments from the life sciences innovator.

Discover timely updates on key initiatives including NARCAN distribution, government contract awards, and advancements in vaccine manufacturing. Our curated news collection covers earnings reports, partnership announcements, and progress on treatments addressing biological threats like anthrax and smallpox.

Stay informed about Emergent's role in global health security through updates on FDA submissions, manufacturing facility expansions, and collaborations with agencies like BARDA. Content is organized chronologically for easy tracking of operational milestones and financial performance.

Bookmark this page for direct access to verified corporate communications and analysis of how EBS navigates complex regulatory environments while maintaining its position as a critical partner in national preparedness programs.

Rhea-AI Summary

Emergent BioSolutions (NYSE: EBS) announced the FDA's approval to extend the shelf life of NARCAN® Nasal Spray from 24 to 36 months. This marks a significant improvement for this emergency opioid overdose treatment, which is the first FDA-approved nasal naloxone. Doug White, Senior VP, emphasized the extension as part of their ongoing innovation to meet healthcare needs.

In July, Emergent launched a new Generation II NARCAN® device that enhances storage conditions, making the product more accessible in emergencies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.02%
Tags
-
Rhea-AI Summary

Emergent BioSolutions (NYSE: EBS) announced that the FDA has extended the shelf life of NARCAN® Nasal Spray from 24 months to 36 months. This nasal spray is the first intranasal form of naloxone approved for emergency opioid overdose treatment. The company launched the Generation II NARCAN device in July, designed to enhance temperature stability. This extension reflects Emergent's commitment to improving product features for healthcare providers and first responders, addressing the critical needs in opioid overdose situations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.02%
Tags
-
Rhea-AI Summary

Emergent BioSolutions (NYSE:EBS) has completed a $450 million offering of 3.875% Senior Unsecured Notes due 2028. The offering aims to strengthen the company's financial position by repaying $353 million of its revolving credit facility. The remaining funds will support general corporate purposes. These Notes are guaranteed by all subsidiaries that hold debt under credit facilities. The offering is compliant with Rule 144A and Regulation S under the Securities Act, and it is important to note that the Notes are unregistered and subject to regulatory exemptions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.36%
Tags
none
Rhea-AI Summary

Emergent BioSolutions (NYSE:EBS) announced the pricing of its offering of $450 million in 3.875% Senior Unsecured Notes due 2028, increasing from an initial $400 million. The company plans to use $353 million of the proceeds to repay outstanding amounts under its revolving credit facility, with the remainder for general corporate purposes. The offering is set to close on August 7, 2020. The notes are guaranteed by the company’s subsidiaries and will be offered to qualified institutional buyers under Regulation S and Rule 144A of the Securities Act.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.65%
Tags
none
-
Rhea-AI Summary

Emergent BioSolutions (EBS) reported significant growth in Q2 2020, achieving total revenues of $394.7 million, a 62.3% increase from $243.2 million in Q2 2019. The net income surged to $92.7 million, up from a loss of $9.5 million in the prior year. Key drivers include CDMO partnerships related to COVID-19, with a notable $628 million contract from HHS under Operation Warp Speed. Adjusted EBITDA reached $156.1 million, marking a 431% increase. The company revised its full-year revenue guidance upward to $1.5-$1.6 billion, highlighting continued operational strength despite pandemic challenges.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.66%
Tags
-
Rhea-AI Summary

Emergent BioSolutions has secured a contract worth approximately $174 million with AstraZeneca for large-scale manufacturing of the COVID-19 vaccine candidate AZD1222. This agreement, valid through 2021, increases AstraZeneca's total commitment to $261 million. Emergent's Baltimore Bayview facility will handle production, leveraging its extensive capabilities for rapid vaccine manufacturing. As part of the U.S. government's Operation Warp Speed, Emergent aims to enhance public health efforts during the pandemic while preparing for potential future commitments in commercial manufacturing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.46%
Tags
covid-19
Rhea-AI Summary

Emergent BioSolutions (NYSE: EBS) will join the S&P MidCap 400 index effective July 24, 2020. This milestone reflects the company's growth and commitment to public health. Richard S. Lindahl, CFO, stated that this addition signifies progress in maximizing shareholder value through revenue growth and reinvestment in the business. The S&P MidCap 400 serves as a benchmark for mid-sized companies, capturing their performance and unique market characteristics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.17%
Tags
none
-
Rhea-AI Summary

Emergent BioSolutions (NYSE: EBS) will hold a conference call on July 30, 2020, at 5:00 pm ET to discuss Q2 2020 financial results and provide revenue guidance for Q3 and the full year. The call can be accessed via telephone or webcast. Investors can view the live feed through the company’s website.

Emergent is focused on enhancing public health through innovative life sciences solutions, with a mission to protect 1 billion lives by 2030.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.33%
Tags
-
Rhea-AI Summary

Emergent BioSolutions (NYSE: EBS) announced a $75 million investment to expand its Canton, Massachusetts facility, focusing on advanced therapy contract development and manufacturing (CDMO) services. This expansion aims to enhance capabilities in viral vector and gene therapy, with services expected to launch in 2023. The improved facility will enable molecule-to-market CDMO services integrating development, drug substance, and drug product manufacturing across its locations in Gaithersburg and Rockville, Maryland. This strategic move aligns with Emergent's growth plan and enhances its position in public health solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
none
Rhea-AI Summary

Emergent BioSolutions (NYSE: EBS) announced participation in two key virtual investor conferences in June 2020. The events include the BMO 2020 Prescriptions for Success Healthcare Virtual Conference on June 23, featuring a fireside chat at 3:00 PM Eastern, and the Three Part Advisors Virtual East Coast IDEAS Investor Conference on June 24, offering a pre-recorded presentation available from 8:00 AM Eastern. The webcasts will cover recent business developments and financial guidance, accessible via the Emergent website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
conferences
Emergent Biosolutions Inc

NYSE:EBS

EBS Rankings

EBS Stock Data

290.97M
53.04M
3.1%
64.59%
14.97%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
GAITHERSBURG